Red Light Holland Corp. reports developments in legal regulated botanical wellness, natural-product therapeutic research, and regulated consumer products. The Ontario-based company owns Filament Health Corp., a clinical-stage natural botanical therapeutics developer with GMP production capabilities, FDA regulatory engagement, a global clinical research footprint, and PEX010, a patented botanical research compound therapeutic candidate.
Company news commonly covers peer-reviewed clinical data, research-institution distribution of PEX010, exclusive licenses to trial data and related intellectual property, and R&D initiatives based on consensual data collection. Updates also address commercial activities in Europe and North America, including regulated consumer product sales in the Netherlands' legal market and home cultivation kits sold through B2B and direct-to-consumer channels.
Rhelion Life Sciences (TRUFF) reported a further delivery of its subsidiary Filament Health's patented botanical psilocybin drug candidate PEX010 to Germany's first psilocybin compassionate use program for treatment-resistant depression.
The program, authorized by Germany's BfArM under the Ordinance on Medicinal Products for Compassionate Use, operates at the Central Institute of Mental Health in Mannheim and the OVID Clinic in Berlin and has treated patients with PEX010 since April 2026. PEX010 is GMP-manufactured in Canada and certified for release in the European Union by a Qualified Person before shipment. Rhelion views these deliveries as building real-world infrastructure for physician access, import/export, distribution and supervised administration ahead of broader regulated markets. Filament has supported more than 80 research studies globally and supplies PEX010 in standardized 1 mg, 5 mg and 25 mg doses, with a 0.5 mg dose planned.
Rhelion Life Sciences (CSE: RHEL, OTCQB: TRUFF) reported Q1 2027 results for the quarter ended June 30, 2026, its first since acquiring Filament Health on April 29, 2026. The Filament acquisition added pharmaceutical drug development, GMP manufacturing, regulatory, clinical supply and intellectual property capabilities and shifted Rhelion’s focus to R&D of naturally derived psychedelic medicines, led by psilocybin candidate PEX010 and iboga extract IBEX011.
According to Rhelion, Q1 2027 revenue was $0.186M versus $0.553M in Q1 2026, with gross profit of $0.170M versus $0.151M. Net loss widened to $1.889M from $1.046M and adjusted EBITDA loss to $1.0631M from $0.679M. As of June 30, 2026, cash and cash equivalents were $2.598M and short‑term investments in one‑year GICs were $5.017M, with total assets of $21.861M compared with $20.141M a year earlier.
Rhelion Life Sciences (CSE: RHEL, OTCQB: TRUFF) announced that its wholly owned subsidiary Filament Health has been issued a new United States patent titled “Dephosphorylation-Controlled Extraction of Phosphorylatable Psychoactive Alkaloids.” The patent strengthens the intellectual property estate underlying PEX010, Filament’s standardized natural psilocybin drug candidate.
According to Rhelion, PEX010 is manufactured using proprietary patented extraction, purification and stabilization methods and is available in 1, 5 and 25 mg doses, with a 0.5 mg dose planned. PEX010 supports more than 80 studies worldwide. Following this grant, Filament’s portfolio totals 77 issued patents across 13 families in jurisdictions including the United States, Canada, Australia, Israel, Mexico and Europe.
Rhelion Life Sciences (OTCQB: TRUFF), through wholly owned subsidiary Filament Health, has completed shipment of its patented, naturally derived psilocybin drug candidate PEX010 to the University of Washington for an investigator‑initiated Phase 2a trial in cancer‑related anxiety and depression (NCT07336238).
Under a licence agreement, Filament will supply PEX010 as the investigational drug product for a group retreat model of psilocybin therapy in adults with metastatic solid tumors or incurable hematologic malignancies. The study is sponsored and led by Professor Anthony Back, with Filament not acting as trial sponsor. PEX010 supports more than 80 research studies worldwide and is backed by 76 issued patents acquired with Filament on April 30, 2026.
Rhelion Life Sciences (OTCQB: TRUFF) announced that wholly owned subsidiary Filament Health has signed a non-binding letter of intent with San Francisco-based Darmiyan to explore using Darmiyan’s FDA De Novo authorized BrainSee AI brain imaging platform in the design of potential future clinical trials of PEX010, Filament’s patented, standardized, GMP-manufactured natural psilocybin drug candidate.
The parties intend to evaluate BrainSee and Darmiyan’s “Virtual Microscope” technology for identifying, selecting and monitoring individuals with amnestic mild cognitive impairment at elevated risk of progression to Alzheimer’s disease, and to consider voxel-based quantitative imaging outputs as exploratory measures of biological change in early Alzheimer’s research involving PEX010.
Rhelion Life Sciences (OTCQB: TRUFF) appointed Samiuddin Khaja as Chief Financial Officer, effective immediately, as it continues its shift into a focused, research-led life sciences company following the acquisition of Filament Health and the launch of the Rhelion Life Sciences identity.
Khaja is an internationally designated CPA with over 15 years of global finance and accounting experience and has led finance functions for public and private companies, including in the psychedelic sector. Keith Li is stepping down as CFO after supporting Rhelion through key corporate development and the Filament acquisition and integration. Rhelion is now concentrating on pharmaceutical drug development, GMP manufacturing and regulated supply of naturally derived psychedelic drug candidates, supported by 76 issued patents, a Health Canada Dealer's Licence, FDA IND experience and a global clinical supply platform backing more than 80 clinical studies.
Rhelion Life Sciences (OTCQB: TRUFF), through its wholly owned subsidiary Filament Health, has signed a licence agreement with University Health Network (UHN) in Toronto to supply its patented, naturally derived psilocybin drug candidate PEX010 for the randomized clinical trial PSI-PARK.
According to Rhelion Life Sciences, PSI-PARK (“Evaluating the Use of Psilocybin to Treat Parkinson's Depression: A Randomized Clinical Trial”) will study psilocybin for depression in people with Parkinson’s disease. UHN sponsors the trial, with Dr. Joshua Rosenblat as principal investigator; Filament supplies PEX010 but is not responsible for trial conduct.
The company highlights Parkinson’s depression as a significant unmet need and notes prior open-label pilot data showing sustained mood improvements without serious adverse events. PEX010 supports more than 80 research studies worldwide and is produced under GMP with standardized doses from 0.5 mg to 25 mg. On April 30, 2026, Rhelion completed its acquisition of Filament, adding 76 issued patents across 15 families and consolidating PEX010 as its lead drug candidate.
Rhelion Life Sciences Corp. (CSE: RHEL, OTCQB: TRUFF, FSE: 4YX) has completed its corporate name change from Red Light Holland Corp. and changed its Canadian Securities Exchange ticker from TRIP to RHEL. Common shares will begin trading under the new name and symbol on the CSE at market open on August 7, 2026, with new CUSIP 76206T108 and ISIN CA76206T1084.
According to the company, no action is required from shareholders, and existing share and warrant certificates remain valid. The rebrand follows the acquisition of Filament Health and is intended to reflect Rhelion’s evolution into a science‑driven life sciences company focused on discovering, developing and commercializing naturally derived psychedelic medicines, supported by expanding clinical programs, intellectual property and pharmaceutical manufacturing capabilities.
Red Light Holland (OTCQB: TRUFF) reported audited results for fiscal 2026 and outlined its transition to Rhelion Life Sciences following the acquisition of Filament Health. Revenue was $4.195M versus $4.944M in 2025, with gross profit of $1.591M and a larger EBITDA loss of $6.754M. Cash declined to $8.471M and total assets to $14.570M.
The Filament deal created a vertically integrated psychedelic drug platform with 76 issued patents, GMP manufacturing, a Health Canada Level 8 Dealer's Licence and botanical psilocybin candidate PEX010, which has completed Phase I and is Phase II-ready. The company supports more than 80 clinical studies and plans a corporate rebrand to Rhelion Life Sciences effective August 4, 2026, while keeping existing stock symbols.
Red Light sold SR Wholesale for €150,000, suspended shiitake production at AEM New Brunswick, is exploring options for MiniChamp and may monetize AEM Ontario farmland appraised at CAD$2M as it refocuses on pharmaceutical-grade psychedelic development, licensing and strategic partnerships.
Red Light Holland (OTCQB: TRUFF) will change its corporate name to Rhelion Life Sciences Corp, pending CSE approval, to reflect its evolution into a focused, science-driven psychedelic drug discovery and development platform following the completed acquisition of Filament Health.
Under the Rhelion brand, the company plans to leverage Filament’s patented, naturally derived psilocybin drug candidate PEX010, its clinical and compassionate use network, and expanded pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities. Filament recently added a 0.5 mg dose to existing 1, 5 and 25 mg strengths, enabling standardized dosing from microdosing to full therapeutic levels.
According to the company, PEX010 is protected by a broad patent portfolio, has a demonstrated 36‑month shelf life, and has been supplied to more than 80 academic and philanthropic research studies worldwide, supporting its strategy as a clinical and research-led psychedelic enterprise.